Executive Profiles

Christine A. White, M.D.
Vice President, Medical Affairs

Christine A. White, M.D., Vice President, Medical Affairs at IDEC Pharmaceuticals, was responsible for leading clinical development of Zevalin™, the first radioimmunotherapy approved by the FDA. Dr. White joined IDEC in June 1996 as a Senior Director, Clinical Oncology and Hematology, having been an investigator for Rituxan® clinical trials, and was a significant contributor to the BLA for Rituxan. In August 2000 she was promoted to Vice President, Oncology and Hematology, and in May 2001 to Vice President, Medical Affairs.

Dr. White led the clinical BLA preparation and presented a summary of this data at the Oncology Drugs Advisory Committee (ODAC) meeting for Zevalin in Washington, DC on September 11, 2001. She has authored numerous academic publications and presentations.

Prior to joining IDEC, Dr. White served as Director of Clinical Oncology Research from 1994 to 1996 at the Sidney Kimmel Cancer Center and Sharp Health Care in San Diego, California. From 1984 to 1994, she was on staff at Scripps Memorial Hospitals, La Jolla and Encinitas, California, where she served as Medical Director of Oncology Research from 1989 to 1994, and Department of Medicine Chair, in 1994. She was an Assistant Professor at UCSD/VA Hospital from 1983-1984.

Dr. White is a member of American Society of Clinical Oncology, American Society of Hematology, American Association of Cancer Research, American Society of Therapeutic Radiation Oncology, International Society for Biological Therapy of Cancer, and a past member of Sigma Xi Scientific Research Society.